Morales Jose, Al Qahtani Masaoud, Khandekar Rajiv, Al Shahwan Sami, Al Odhayb Sami, Al Mobarak Faisal, Edward Deepak P
*King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia †Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
J Glaucoma. 2015 Aug;24(6):e157-62. doi: 10.1097/IJG.0000000000000228.
To evaluate changes in intraocular pressure (IOP), vision, and medications at least 1 year after phacoemulsification combined with endocyclophotocoagulation for advanced glaucoma and cataract.
A retrospective chart review was conducted on patients with advanced glaucoma who underwent phacoemulsification combined with endocyclophotocoagulation at King Khaled Eye Specialist Hospital between 2005 and 2012. Data were collected on patient demographics, type of glaucoma, IOP over time, best-corrected visual acuity, number of glaucoma medications, comorbidities, and previous surgeries. Absolute success was defined as IOP≤15 mm Hg without medication and qualified success was IOP≤15 mm Hg with medications. Statistical significance was indicated by P<0.05.
The study sample comprised 104 eyes (104 patients). Mean follow-up was 17.3±1.8 months. Mean IOP decreased from 17±1.4 mm Hg preoperatively to 14.7±1.3 mm Hg at the last postoperative visit. Absolute success was achieved in 11.9% (95% confidence interval, 5.6-18.2) of the eyes. Qualified success was achieved in 72.3% (95% confidence interval, 63.5-81.0) of the eyes. Best-corrected visual acuity improved by ≥2 lines in 76 (73%) eyes. Eyes with primary open-angle glaucoma had the higher absolute and qualified success rates compared with primary angle-closure and pseudoexfoliation glaucoma (P>0.05). Only 48 (46%) patients required >3 medications for IOP control compared with 78 (75%) patients before surgery.
At ≥1 year postoperatively, the absolute success rate of treating advanced glaucoma by endocyclophotocoagulation and phacoemulsification was low. However, medication burden was reduced. Owing to the significant variation in the success rate based on the type of glaucoma, patients with advanced glaucoma should be carefully selected and counseled.
评估超声乳化白内障吸除联合睫状体光凝术治疗晚期青光眼合并白内障至少1年后的眼压、视力及用药情况变化。
对2005年至2012年在沙特国王哈立德眼科专科医院接受超声乳化白内障吸除联合睫状体光凝术的晚期青光眼患者进行回顾性病历分析。收集患者的人口统计学资料、青光眼类型、眼压随时间变化情况、最佳矫正视力、青光眼用药数量、合并症及既往手术情况。绝对成功定义为眼压≤15mmHg且无需用药,合格成功定义为眼压≤15mmHg且需用药。P<0.05表示差异有统计学意义。
研究样本包括104只眼(104例患者)。平均随访时间为17.3±1.8个月。平均眼压从术前的17±1.4mmHg降至末次随访时的14.7±1.3mmHg。11.9%(95%置信区间,5.6-18.2)的患眼达到绝对成功。72.3%(95%置信区间,63.5-81.0)的患眼达到合格成功。76只(73%)患眼的最佳矫正视力提高了≥2行。原发性开角型青光眼患眼的绝对成功率和合格成功率高于原发性闭角型青光眼和剥脱性青光眼(P>0.05)。与术前78例(75%)患者相比,仅48例(46%)患者眼压控制需要>3种药物。
术后≥1年,睫状体光凝联合超声乳化白内障吸除术治疗晚期青光眼的绝对成功率较低。然而,用药负担减轻。由于青光眼类型导致成功率存在显著差异,对于晚期青光眼患者应谨慎选择并给予建议。